Uro Onc Course

Moderator(s)

• 

  Elio Mazzone
• 

  Senthil Nathan, MS FRCS FEBU MPhil (he/him/his)

  Prof & Chair of Urology
  Cleveland Clinic London
  London, United Kingdom
• CS

  Chiara Sighniofli
• 

  Anthony Costello, MBBS, FRCSI, FRACS, MD

  Professor of Surgery, Robotic Proctor
  International Medical Robotics Association, Dept of Surgery, University of Melbourne Victoria
  North Melbourne, Victoria, Australia
• 

  Bernardo Rocco

Presentations:

• 8:00 AM - 8:05 AM CEST

  Introduction to the course and Welcome
  

  Faculty: Vipul R. Patel, MD – AdventHealth Global Robotics Institute

  Faculty: Brian Miles

  Faculty: Marcio Covas Moschovas – AdventHealth Global Robotics Institute
• 8:05 AM - 8:15 AM CEST

  Current Literature on High-risk prostate cancer: Best articles of 2024/25 and current literature on High-risk pCa
  

  Speaker: Marcio Covas Moschovas – AdventHealth Global Robotics Institute
• 8:15 AM - 8:25 AM CEST

  Prostate cancer screening and diagnosis: Genetic tests applications in High-risk PCa (Decipher, 4k, PHI, GPS, urinary markers, exosomes, etc). Do we have benefits? When should I order?
  

  Speaker: John Davis
• 8:25 AM - 8:35 AM CEST

  Prostate cancer screening and diagnosis: Current status of MRI and PET Scan in High-Risk prostate cancer staging (PSMA, Axumin, Fluoride, etc)
  

  Speaker: Justin Emtage
• 8:35 AM - 8:45 AM CEST

  Prostate cancer screening and diagnosis: Adverse pathology in PCa biopsy (cribriform, intraductal, small cell): implications on the treatment
  

  Speaker: Marcelo Orvieto
• 8:45 AM - 8:50 AM CEST

  Prostate cancer screening and diagnosis: Q+A
  

  Panelist: Marcio Covas Moschovas – AdventHealth Global Robotics Institute

  Panelist: John Davis

  Panelist: Justin Emtage

  Panelist: Marcelo Orvieto, n/a – Department of Urology, Clínica Alemana, Santiago, Chile
• 8:50 AM - 9:00 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: Genomic test applications in high-risk and patients with family history of PCa: When should I use? Pre-Recorded lecture
  

  Speaker: Elena Efstathiou
• 9:00 AM - 9:10 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: Neoadjuvant Hormone deprivation therapy: where do we stand?
  

  Speaker: Justin Emtage
• 9:10 AM - 9:20 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: The role and extent of lymph node dissection in the PET-PSMA ERA
  

  Speaker: Karim Touijer
• 9:20 AM - 9:30 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: Radiation protocols in HR disease ( prostate RT vs. Prostate and pelvis vs. prostate lesion RT boost) Pre-Recorded lecture
  

  Speaker: Bridget Koontz
• 9:30 AM - 9:40 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: The role of Focal Therapy in High-grade prostate cancer. Should we do it?
  

  Speaker: Brian Miles
• 9:40 AM - 9:50 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: Surgical Margins Impacts and postoperative management in high-risk prostate cancer
  

  Speaker: Rafael Coelho
• 9:50 AM - 10:00 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: Neurosafe, Confocal and real time positive surgery margins evaluation. Where do we stand?
  

  Speaker: Chiara Sighniofli
• 10:00 AM - 10:30 AM CEST

  High-Risk and Locally Advanced Prostate Cancer: Clinical cases discussion- Challenging cases of prostate cancer: experience from a high-volume referral center
  

  Speaker: Marcio Covas Moschovas – AdventHealth Global Robotics Institute

  Speaker: Chiara Sighniofli

  Speaker: Christian Wagner
• 10:30 AM - 10:50 AM CEST

  Break
• 10:50 AM - 11:00 AM CEST

  Recurrent Disease After Local Treatment: Applications of PSMA Pet in staging PCa recurrence. When should I order and how should I do the interpretation?
• 11:00 AM - 11:10 AM CEST

  Recurrent Disease After Local Treatment: PSA persistence after surgery : medical oncologist approach (Pre-Recorded Lecture)
  

  Speaker: Guru Sonpavde
• 11:10 AM - 11:20 AM CEST

  Recurrent Disease After Local Treatment: PSA persistence after surgery: when is the best time and optimal candidates to undergo Salvage RT
  

  Speaker: John Davis
• 11:20 AM - 11:30 AM CEST

  Recurrent Disease After Local Treatment: Selecting the best salvage treatment after non-surgical treatment failure for localized prostate cancer? Surgery vs. RT vs. Ablation
  

  Speaker: Senthil Nathan
• 11:30 AM - 11:40 AM CEST

  Recurrent Disease After Local Treatment: Managing PCa with lymph node recurrence: how to optimize results? Salvage Lymphadenectomy vs. RT protocols.
  

  Speaker: Anthony Costello
• 11:40 AM - 11:50 AM CEST

  Oligometastatic disease: Current role of RT + Hormone deprivation in Oligometastatic disease. Should we use ADT in all candidates? Should we irradiate the metastasis as well?
  

  Speaker: Bridget Koontz
• 11:50 AM - 12:00 PM CEST

  Oligometastatic disease: Current role of surgery in Oligometastatic disease
  

  Speaker: Bernardo Rocco
• 12:00 PM - 12:15 PM CEST

  Urologic Oncology Q + A
  

  Panelist: John Davis

  Panelist: Senthil Nathan

  Panelist: Anthony Costello

  Panelist: Bernardo Rocco
• 8:15 PM - 8:40 AM CEST

  Morning Moderators
  

  Moderator: Brian Miles

  Moderator: John Davis

  Moderator: Marcelo Orvieto, n/a – Department of Urology, Clínica Alemana, Santiago, Chile

  Moderator: Alejandro Rodriguez